| 13.29 -0.15 (-1.12%) | 05-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 16.4 | 1-year : | 18.03 |
| Resists | First : | 14.04 | Second : | 15.43 |
| Pivot price | 14.02  |
|||
| Supports | First : | 11.8 | Second : | 9.81 |
| MAs | MA(5) : | 13.54 |
MA(20) : | 14.19 |
| MA(100) : | 12.46  |
MA(250) : | 12.28 |
|
| MACD | MACD : | 0 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 15.7 |
D(3) : | 17.9 |
| RSI | RSI(14): 45.1 |
|||
| 52-week | High : | 18.51 | Low : | 7.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SPRY ] has closed above bottom band by 10.4%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 13.68 - 13.76 | 13.76 - 13.84 |
| Low: | 12.75 - 12.83 | 12.83 - 12.92 |
| Close: | 13.13 - 13.28 | 13.28 - 13.44 |
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Wed, 07 May 2025
ARS Pharmaceuticals Inc Cash Price For Neffy Is $199 For Two Doses On GoodRx Website - marketscreener.com
Mon, 05 May 2025
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results - GlobeNewswire
Mon, 05 May 2025
ARS Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Expected on Anaphylaxis Treatment Progress - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 98 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 21.1 (%) |
| Held by Institutions | 76.1 (%) |
| Shares Short | 16,730 (K) |
| Shares Short P.Month | 17,150 (K) |
| EPS | 0.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.61 |
| Profit Margin | 8.9 % |
| Operating Margin | 54.5 % |
| Return on Assets (ttm) | -0.7 % |
| Return on Equity (ttm) | 3.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.69 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -0.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 14 (M) |
| Levered Free Cash Flow | 9 (M) |
| PE Ratio | 166.12 |
| PEG Ratio | 0 |
| Price to Book value | 5.07 |
| Price to Sales | 14.64 |
| Price to Cash Flow | 96.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|